Skip to main content
Canna~Fangled Abstracts

Impact of deceased organ donor marijuana use on donor culture positivity and solid organ transplant recipient outcomes

By February 23, 2024March 23rd, 2024No Comments


doi: 10.1016/j.ajt.2024.02.022.

Online ahead of print.
Affiliations 

Abstract

With the increasing prevalence of marijuana use in the US, many deceased organ donors have a history of marijuana use, raising concerns about infectious risks to transplant recipients. We performed a multicenter retrospective cohort study in which exposed donors were those with recent marijuana use (in the prior 12 months) and unexposed donors were those with no recent marijuana use. Primary outcomes included the following: (1) positive donor cultures for bacteria or fungi, (2) recipient infection due to bacteria or fungi within 3 months posttransplant, and (3) recipient graft failure or death within 12 months posttransplant. Multivariable regression was used to evaluate the relationship between donor marijuana use and each outcome. A total of 658 recipients who received organs from 394 donors were included. Recent marijuana use was not associated with donor culture positivity (aOR: 0.84, 95% CI: 0.39-1.81, P = .65), recipient infection (aHR: 1.02, 95% CI: 0.76-1.38, P = .90), or recipient graft failure or death (aHR: 1.65, 95% CI: 0.90-3.02, P = .11). Our data suggest that organs from donors with a history of recent marijuana use do not pose significant infectious risks in the early posttransplant period.

Keywords: donor selection, donor substance use, donor-derived infection, transplant infectious disease

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Emily Blumberg receives research support from Merck, Takeda, Hologic, and Scynexis; was a member of a Data and Safety Monitoring Board (DSMB) for Amplyx; and is a member of Scientific Advisory Committees for Merck and Takeda. Jennifer Han was affiliated with the University of Pennsylvania during the conduct of this research and is now employed by, and holds shares in, the GlaxoSmithKline group of companies. Ebbing Lautenbach is a member of a DSMB for Merck and is a member of a scientific advisory committee for Paratek and Shionogi. None of these conflicts are relevant to this article. All other authors report no disclosures.

Similar articles

LinkOut – more resources


Leave a Reply